

4<sup>th</sup> July 2019

~ Breaking News! ~

We are very excited to tell you about the most recent development in repurposing drugs for IIH.

Invex Therapeutics is a new company co-founded by Prof. Sinclair focussed on the development of treatments for Idiopathic Intracranial Hypertension (IIH) and other conditions in which raised intracranial pressure is problematic.

As a charity devoted to patient support we see and hear on a daily basis the suffering that many people with IIH go through, currently there are no drugs designed specifically to treat IIH and patient outcomes are often poor. Prof Sinclair's research on Exenatide is ground breaking and for IIH patients worldwide the prospect of reformulating it to make it specific for IIH is truly amazing. To have a drug especially designed to treat the main symptom of IIH; raised intracranial pressure, is long awaited.

You may well be aware that reformulating drugs and the research required to ensure their efficacy and safety does not come cheap, orphan drugs are intended to treat diseases so rare that sponsors are reluctant to develop them under usual marketing conditions so we are very excited to see the formation of Invex Therapeutics. The company is raising \$12,000,000 from the sale of shares to continue the repurposing and commercialisation of Exenatide through the execution of a series of development and other activities.

Delighted at this news our Chair Shelly Williamson has said 'I am delighted to see the formation of Invex Therapeutics whose mission is to bring through new drugs for raised intracranial pressure and Idiopathic Intracranial Hypertension (IIH). It is vitally important that we can have effective safe drugs for IIH that are well tolerated. These are exciting times, and only with strong links between research academics, industry and patients can we make progress and bring new drugs through to improve patient care.'